Literature DB >> 12538549

Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.

Tony Antoniou1, Thea Weisdorf, Kevin Gough.   

Abstract

Prolonged exposure to highly active antiretroviral therapy may be associated with adverse effects related to mitochondrial toxicity, such as hyperlactatemia. We describe a case of symptomatic hyperlactatemia in an HIV-positive patient to illustrate the subtle clinical symptoms and abnormal laboratory test results associated with this condition. We also review the pathophysiology, prevalence, spectrum and management of disturbances in lactate homeostasis induced by nucleoside reverse transcriptase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538549      PMCID: PMC140430     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  30 in total

1.  Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series.

Authors:  J Delgado; M Harris; A Tesiorowski; J S Montaner
Journal:  Clin Infect Dis       Date:  2001-11-12       Impact factor: 9.079

2.  Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.

Authors:  S E Lim; W C Copeland
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

3.  Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.

Authors:  M John; C B Moore; I R James; D Nolan; R P Upton; E J McKinnon; S A Mallal
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

4.  Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  K Boubaker; M Flepp; P Sudre; H Furrer; A Haensel; B Hirschel; K Boggian; J P Chave; E Bernasconi; M Egger; M Opravil; M Rickenbach; P Francioli; A Telenti
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

5.  Emerging role of riboflavin in the treatment of nucleoside analogue-induced type B lactic acidosis.

Authors:  S D Dalton; A R Rahimi
Journal:  AIDS Patient Care STDS       Date:  2001-12       Impact factor: 5.078

6.  Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

Authors:  A A Johnson; A S Ray; J Hanes; Z Suo; J M Colacino; K S Anderson; K A Johnson
Journal:  J Biol Chem       Date:  2001-08-28       Impact factor: 5.157

7.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

Authors:  A Carr; J Miller; M Law; D A Cooper
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

8.  Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

Authors:  Gabriel Birkus; Michael J M Hitchcock; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature.

Authors:  Vicente Falcó; Dolors Rodríguez; Esteban Ribera; Esteban Martínez; José Maria Miró; Pere Domingo; Ruth Diazaraque; José R Arribas; Juan J González-García; Francesc Montero; Lluis Sánchez; Albert Pahissa
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

10.  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Authors:  Hélène C F Côté; Zabrina L Brumme; Kevin J P Craib; Christopher S Alexander; Brian Wynhoven; Lillian Ting; Hubert Wong; Marianne Harris; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

View more
  1 in total

Review 1.  Adverse effects of antiretroviral therapy for HIV infection.

Authors:  Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.